Bio-Techne Corp. plans to sell its Exosome Diagnostics Inc. business to Mdxhealth SA for $15 million plus royalty payments, a steep cut from the $250 million the company paid to acquire Exodx in 2018.

Jazz Pharmaceuticals plc is prepped and ready for launch following U.S. FDA accelerated approval of dordaviprone as the first systemic therapy for H3 K27M-mutant diffuse glioma. Branded Modeyso, the ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

In the tumor microenvironment, cancer cells activate various signaling pathways to promote their growth. This includes the ...

The U.S. FDA has staked out a position on the use of per- and polyfluoroalkyl substances in medical devices, declaring that ...

The U.S. Department of Health and Human Services has tapped Sean Keveney for the job of FDA chief counsel, but the recent ...

Cancel culture continues at the U.S. Department of Health and Human Services (HHS) as it observes National Immunization ...

Precision medicine is becoming a reality in Asia Pacific as more targeted therapies are being developed that are tailored to ...

T-cell engagers (TCEs) are a new class of immuno-oncology therapies that have proven effective for the treatment of both ...

Glioblastoma, one of the most lethal brain cancers, remains a challenge to treat despite advancements in conventional ...

Chronic infection with hepatitis B virus affects around a quarter of a billion people globally, and it can increase risk of ...

The fibroblast growth factor 21 (FGF21) analogue space took another turn as Novo Nordisk A/S said during its second-quarter financial update that work with zalfermin (NNC0194-0499) will be ...